Sanofi-logo

For US Healthcare Professional use only.
The safety and efficacy of these investigational agents have not been established.
amlitelimab-stream-ad-thumb
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate-to-severe Atopic Dermatitis (STREAM-AD)
View Scan and Download
thumb
Long-term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate-to-severe Atopic Dermatitis Clinical Trials (RIVER-AD)
View Scan and Download
thumb
An Open-label, Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Atopic Dermatitis (ATLANTIS)
View Scan and Download
thumb
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1)
View Scan and Download
thumb
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
View Scan and Download
thumb
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate-to-severe Atopic Dermatitis (HYDRO)
View Scan and Download
thumb
A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444656 (KT-474) in Adult Participants With Moderate-to-severe Atopic Dermatitis (ADVANTA)
View Scan and Download
thumb
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE)
View Scan and Download

Privacy & Data Protection        Cookies Policy
Does not include study cards for clinical programs of dupilumab.

MAT-US-2401225 v1.0 - P Exp. Date: 02/12/2026
© 2024 Sanofi. All rights reserved.